导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.89% | 2779/4773 |
| 近一周 | -2.45% | 2204/5462 |
| 近一月 | -6.06% | 3432/5421 |
| 近一季 | 11.77% | 132/5209 |
| 近半年 | 0.82% | 1113/4920 |
| 近一年 | -15.33% | 3690/4366 |
| 近两年 | 18.61% | 2672/2954 |
| 近三年 | -10.52% | 2041/2253 |
| 成立以来 | -9.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.74% 3382/4961 |
-3.54% 3460/5312 |
- - |
- - |
| 2025 | 4.91% 3024/4813 |
0.71% 1784/3635 |
1.44% 2330/4076 |
19.80% 2095/4524 |
-14.28% 4337/4813 |
| 2024 | -11.82% 2360/3463 |
-11.22% 2419/2808 |
-9.48% 2365/3014 |
21.24% 604/3129 |
-9.50% 2930/3463 |
| 2023 | -13.38% 1538/2656 |
-1.52% 1872/2280 |
-9.13% 2037/2385 |
0.51% 364/2515 |
-3.70% 766/2655 |
| 2022 | -23.31% 1125/2207 |
-14.58% 974/1919 |
2.22% 1329/2016 |
-18.27% 1691/2113 |
7.46% 308/2208 |
| 2021 | -15.08% 1154/1822 |
-3.83% 828/1255 |
14.29% 259/1330 |
-16.20% 1396/1466 |
-7.81% 1574/1822 |
| 2020 | 53.24% 151/1250 |
3.36% 121/1028 |
26.68% 140/1067 |
5.03% 933/1164 |
11.44% 542/1184 |
| 2019 | 39.91% 266/1092 |
26.69% 386/739 |
-3.93% 410/788 |
7.50% 84/850 |
6.93% 513/918 |
| 2018 | -17.80% 133/834 |
- - |
5.89% 6/631 |
-12.24% 609/660 |
-20.63% 674/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达医药ETF联接A VS. 长安沪深300非周期A(740101) |